- Home
- Publications
- Publication Search
- Publication Details
Title
Ixazomib for the treatment of multiple myeloma
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 19, Issue 17, Pages 1949-1968
Publisher
Informa UK Limited
Online
2018-11-14
DOI
10.1080/14656566.2018.1528229
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
- (2018) Xavier Leleu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma
- (2018) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
- (2018) Jesús F. San-Miguel et al. HAEMATOLOGICA
- NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
- (2018) Shaji K. Kumar et al. Journal of the National Comprehensive Cancer Network
- The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies
- (2018) Parameswaran Hari et al. Journal of Geriatric Oncology
- A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
- (2018) Jesús F. San-Miguel et al. HAEMATOLOGICA
- Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
- (2017) María-Victoria Mateos et al. HAEMATOLOGICA
- Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival—In Most
- (2017) Joseph R. Mikhael JOURNAL OF CLINICAL ONCOLOGY
- Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
- (2017) Jian Hou et al. Journal of Hematology & Oncology
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
- (2017) A Krishnan et al. LEUKEMIA
- RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
- (2017) E Viziteu et al. LEUKEMIA
- Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
- (2017) Neeraj Gupta et al. Targeted Oncology
- Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma
- (2017) N Tandon et al. Blood Cancer Journal
- A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
- (2017) A K Mitra et al. Blood Cancer Journal
- Emerging drugs and combinations to treat multiple myeloma
- (2017) Alessandra Larocca et al. Oncotarget
- Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
- (2017) María-Victoria Mateos et al. HAEMATOLOGICA
- Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
- (2017) Sarah A Holstein et al. Lancet Haematology
- Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials
- (2016) Maria-Victoria Mateos et al. ANNALS OF HEMATOLOGY
- Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
- (2016) H. Avet-Loiseau et al. BLOOD
- Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
- (2016) S. K. Kumar et al. BLOOD
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- The effects of proteasome inhibitors on bone remodeling in multiple myeloma
- (2016) Maurizio Zangari et al. BONE
- Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
- (2016) Neeraj Gupta et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Multiple myeloma: practice patterns across Europe
- (2016) Marc S. Raab et al. BRITISH JOURNAL OF HAEMATOLOGY
- A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis
- (2016) Neeraj Gupta et al. BRITISH JOURNAL OF HAEMATOLOGY
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
- (2016) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Trends in overall survival and costs of multiple myeloma, 2000–2014
- (2016) R Fonseca et al. LEUKEMIA
- Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma
- (2016) Kevin Barley et al. LEUKEMIA & LYMPHOMA
- A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
- (2016) Katja Weisel et al. LEUKEMIA & LYMPHOMA
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
- (2016) Sundar Jagannath et al. Expert Review of Hematology
- Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
- (2016) J R Jones et al. Blood Cancer Journal
- The role of maintenance therapy in multiple myeloma
- (2016) B Lipe et al. Blood Cancer Journal
- Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study
- (2015) María Victoria Mateos et al. AMERICAN JOURNAL OF HEMATOLOGY
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
- (2015) A. Palumbo et al. BLOOD
- Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis
- (2015) Neeraj Gupta et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Molecular basis of resistance to proteasome inhibitors in hematological malignancies
- (2015) Denise Niewerth et al. DRUG RESISTANCE UPDATES
- Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
- (2015) David C. Smith et al. INVESTIGATIONAL NEW DRUGS
- Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
- (2015) Neeraj Gupta et al. Journal of Hematology & Oncology
- Multiple myeloma
- (2015) Christoph Röllig et al. LANCET
- Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
- (2015) J Laubach et al. LEUKEMIA
- When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response
- (2015) S. P. Shah et al. MOLECULAR CANCER RESEARCH
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life
- (2015) R. Baz et al. SUPPORTIVE CARE IN CANCER
- Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations
- (2015) Helena Maes et al. Expert Review of Hematology
- Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
- (2015) S K Kumar et al. Blood Cancer Journal
- Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
- (2015) Fabrizio Accardi et al. Biomed Research International
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
- (2014) J. Martinez-Lopez et al. BLOOD
- Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
- (2014) P. G. Richardson et al. BLOOD
- Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life
- (2014) Thomas R Osborne et al. BMC CANCER
- Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease
- (2014) A. Garcia-Gomez et al. CLINICAL CANCER RESEARCH
- Maintenance therapy in newly diagnosed multiple myeloma: current recommendations
- (2014) Annamaria Brioli et al. Expert Review of Anticancer Therapy
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
- (2014) Shaji K Kumar et al. LANCET ONCOLOGY
- Improved long-term survival in multiple myeloma up to the age of 80 years
- (2014) S Y Kristinsson et al. LEUKEMIA
- Current treatment landscape for relapsed and/or refractory multiple myeloma
- (2014) Meletios A. Dimopoulos et al. Nature Reviews Clinical Oncology
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
- (2014) Massimo Offidani et al. OncoTargets and Therapy
- Current strategies for treatment of relapsed/refractory multiple myeloma
- (2014) Jacob P Laubach et al. Expert Review of Hematology
- Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
- (2014) S E Assouline et al. Blood Cancer Journal
- Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
- (2013) F. Gay et al. BLOOD
- Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis
- (2013) Samantha Pozzi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
- (2013) Chungyee Leung-Hagesteijn et al. CANCER CELL
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Minimal Residual Disease in Multiple Myeloma
- (2013) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials
- (2013) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Review of health-related quality of life data in multiple myeloma patients treated with novel agents
- (2013) P Sonneveld et al. LEUKEMIA
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
- (2013) Joseph R. Mikhael et al. MAYO CLINIC PROCEEDINGS
- Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
- (2012) M.-V. Mateos et al. BLOOD
- IMWG consensus on maintenance therapy in multiple myeloma
- (2012) H. Ludwig et al. BLOOD
- Proteasome inhibitors in multiple myeloma: 10 years later
- (2012) P. Moreau et al. BLOOD
- Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
- (2012) P. L. Bergsagel et al. BLOOD
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
- (2011) K. Neben et al. BLOOD
- Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
- (2011) P. Moreau et al. BLOOD
- Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma
- (2011) Ann Kristin Kvam et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1
- (2011) S. C. W. Ling et al. HAEMATOLOGICA
- Management of treatment-emergent peripheral neuropathy in multiple myeloma
- (2011) P G Richardson et al. LEUKEMIA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data
- (2011) D. Pulte et al. ONCOLOGIST
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- (2010) E. Kupperman et al. CANCER RESEARCH
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations
- (2009) Ann Kristin Kvam et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study
- (2009) Ingemar Turesson et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More